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Abstract
Background: Current guidelines for the treatment of adult severe traumatic brain injury (sTBI) consist of high-quality
evidence reports, but they are no longer accompanied by management protocols, as these require expert opinion to
bridge the gap between published evidence and patient care. We aimed to establish a modern sTBI protocol for adult
patients with both intracranial pressure (ICP) and brain oxygen monitors in place.
Methods: Our consensus working group consisted of 42 experienced and actively practicing sTBI opinion leaders
from six continents. Having previously established a protocol for the treatment of patients with ICP monitoring alone,
we addressed patients who have a brain oxygen monitor in addition to an ICP monitor. The management protocols
were developed through a Delphi-method-based consensus approach and were finalized at an in-person meeting.
Results: We established three distinct treatment protocols, each with three tiers whereby higher tiers involve therapies with higher risk. One protocol addresses the management of ICP elevation when brain oxygenation is normal.
A second addresses management of brain hypoxia with normal ICP. The third protocol addresses the situation when
both intracranial hypertension and brain hypoxia are present. The panel considered issues pertaining to blood transfusion and ventilator management when designing the different algorithms.
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Conclusions: These protocols are intended to assist clinicians in the management of patients with both ICP and
brain oxygen monitors but they do not reflect either a standard-of-care or a substitute for thoughtful individualized
management. These protocols should be used in conjunction with recommendations for basic care, management of
critical neuroworsening and weaning treatment recently published in conjunction with the Seattle International Brain
Injury Consensus Conference.
Keywords: Brain injury, Head trauma, Algorithm, Protocol, Consensus, Intracranial pressure, Brain oxygen, Tiers,
Seattle, SIBICC, PbtO2

Introduction
The Seattle International Brain Injury Consensus Conference (SIBICC) [1] used a Delphi-method based consensus approach in an attempt to bridge the gap between the
severe traumatic brain injury (sTBI) guidelines available
for individual treatments [2] and the lack of evidence on
how such treatments should be integrated into a practical
management algorithm. The result, a protocol based on
the formalized consensus of 42 international, multidisciplinary neurotrauma experts, provides class III evidence
to guide the management of sTBI patients with intracranial pressure (ICP) as their only monitored brain-specific
parameter [1]. During this process, the group expressed
a desire to additionally address multi-modality monitoring if possible. They strongly supported brain tissue
oxygen (PbtO2) monitoring as their first choice for the
second parameter. Indeed, the evidence suggesting that
sTBI clinical care informed by PbtO2 measures may lead
to improved clinical outcomes is growing [3]. This paper
thus presents the second product of the SIBICC meeting,
an algorithm for managing adult sTBI patients based on
combined monitoring of ICP and PbtO2.
Methods
The methods were the same as used in the ICP-only
work (see also supplementary methods) [1]. Fortytwo international intensivists, neurosurgeons, trauma
surgeons, and emergency medicine physicians from
six continents comprised the SIBICC consensus
working group (CWG). We based panel selection on
(a) > 10 years clinical experience in sTBI; (b) current,
active involvement in acute care management of sTBI
patients; (c) representation of involved disciplines; (d)
geographic diversity; (e) ability to commit time to the
algorithm development process. We calculated panel
size based on logistic considerations. Panelists completed conflict of interest forms relevant to sTBI management. There were no conflicts mandating recusal of
any participant.
The expressed focus of the effort was to design a
management algorithm that would be acceptable to the
panel and amenable to application in both neurological

and general ICUs by physicians not specialized in neurointensive care. A priori, we specified that the threshold for consensus would be 80% or greater agreement
by at least 80% of the voting panelists. Prior to the
meeting, the CWG completed eight web-based surveys
(SurveyMonkey Inc., San Mateo, CA, USA, www.surve
ymonke y.com) to determine the algorithm design and
focus, explore definitions and thresholds, operationally
define treatment modalities, evaluate acceptability and
tier assignments of treatment modalities, etc. We combined voting results with panelists’ comments to iterate
these surveys to maximize consensus and define areas
requiring focus at the in-person meeting. It was during
this process that the CWG elected to attempt development of an algorithm for combined ICP/PbtO2 monitoring if time allowed.
The in-person SIBICC meeting occurred from the
5th to 7th of April 2019 in Seattle, Washington, USA.
We used anonymous electronic voting and vote analysis (Electronic Media Services Inc., Gig Harbor Washington, USA, www.electronicmeetingser vices.com).
Professional, independent non-physician moderators
facilitated group discussions. Unless specifically modified by the CWG, we limited the voting cycle to three
iterations, interspersed with discussions. An element
formed part of the final recommendations only if it
attained 80% approval. Unresolved issues are reported
as such. We used small group sessions to address complex issues, with the whole CWG modifying and voting
on small group recommendations. Small group discussions relevant to these ‘combined’ algorithms focused
particularly on the complexities of ventilator management and blood transfusion. All recommendations
were incorporated verbatim into the final product.
The CWG recognized the notable time and effort
that the Clinical Standardization Committee involved
in designing the brain oxygen optimization in severe
TBI-phase 3 (BOOST-3) trial had devoted to developing a study protocol to manage combined ICP and
PbtO2 abnormalities in the experimental limb of that
randomized trial. Rather than ignoring the value of
what they had produced in parallel, relevant aspects
of the BOOST-3 protocol were reviewed during the
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development of the SIBICC algorithm. Discussion was
facilitated as several CWG members overlapped both
efforts. Notably, the BOOST-3 protocol was available for information only, and involved neither effort
nor implication to adopt or merge any steps. The CWG
acknowledges the cooperation of the whole BOOST-3
Clinical Standardization Committee in this process (see
“Acknowledgements”).
Donations solicited from industry and other interested
parties funded the in-person meeting. In return, they
were allowed to silently observe the conference, without any interaction with the panelists or the process. No
donors or other outside parties influenced any portion of
these recommendations.

Results
Consensus efforts generated a list of interventions viewed
as fundamental to the care of sTBI patients and which
should ideally be in place early in the course of care
(Fig. 1). These ‘tier zero’ interventions are not dependent
on the presence of ICP elevation. The CWG also generated a list of treatments that should not be used in the

Table 1 Treatment NOT recommended for use in the management of severe traumatic brain injury (when both ICP
and PbtO2 are monitored)
Mannitol by non-bolus continuous intravenous infusion
Scheduled infusion of hyperosmolar therapy (e.g., every 4–6 h)
Lumbar CSF drainage
Furosemide
Routine use of steroids
Routine use of therapeutic hypothermia to temperatures below 35 °C
due to systemic complications
High-dose propofol to attempt burst suppression
Decreasing PaCO2 below 30 mmHg/4.0 kPa
Routinely raising CPP above 90 mmHg
Barbiturates as treatment for low PbtO2 unless barbiturates are otherwise
indicated
Hypothermia as treatment for low PbtO2 unless hypothermia is otherwise
indicated
Hypercarbia in “type D” patients
CPP cerebral perfusion pressure, ICP intracranial pressure, kPa kiloPascals,
PaCO2 arterial partial pressure of carbon dioxide, PbtO2 brain tissue partial
pressure of oxygen

Fig. 1 Consensus-based basic severe traumatic brain injury care for patients with an ICP and brain oxygen monitor in situ. These are basic treatments recommended as fundamental to the care of patients with sTBI, to be initiated (“Expected interventions”) or considered (“Recommended
interventions”) upon ICU admission of a patient with both an ICP and brain oxygen monitor, regardless of the measured values. CO2 carbon dioxide,
CPP cerebral perfusion pressure, Hg hemoglobin, HOB head of bed, ICP intracranial pressure, ICU intensive care unit, spO2 arterial oxygen saturation
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Fig. 2 This matrix provides the schema for the 4 clinical conditions
encountered in patients with both ICP and brain oxygen monitors
in situ. Type A reflects normal values for both monitors and does
not require treatment. Type B involves ICP elevation but normal
brain oxygen values; we propose a distinct treatment algorithm for
such patients than in those with ICP elevation and unknown PbtO2
values. Type C patients have hypoxic brains but normal ICP and Type
D patients have both brain hypoxia and ICP elevation. An ICP of 22
mmHg discriminates normal (lower) and abnormal (higher) values
while PbtO2 values of 20 mmHg discriminates normal (higher) and
abnormal (lower) values. ICP intracranial pressure, PbtO2 partial pressure of brain oxygen

involved in acute post-traumatic (ICU) care by means of
consensus achieved with blinded voting. Such formalized
integration of expert opinion provides the most basic
level of evidence towards organizing and standardizing
care, relevant to all neurotrauma practitioners but particularly to centers not specifically expert in the management of sTBI or those considering initiating combined
ICP/PbtO2 monitoring.
Given the class III status of this evidence, these algorithms should be considered as a suggested treatment
method without proven superiority over other applicable
methods. They represent a safe and modern approach to
sTBI care. They are not a standard of care nor are they
likely to represent the best treatment approach in a given
instance. They are not legally binding and they are not
designed as quality assurance monitoring tools. They do
not represent the approach of any individual CWG member and should not be substituted for thoughtful clinical judgment. Variability within individual patients or
patient cohorts (e.g. center variations) may necessitate
local adaptation, which is entirely within the nature of
this offering.
Algorithm structure

care of patients with sTBI (Table 1), except in special
circumstances. The additional algorithms provided here
use the same three-tier algorithm structure as in the ICPonly algorithm development [1]. To accommodate the
combination of two monitors, a schema consisting of a
2 × 2 table combining the permutations of ICP and PbtO2
status was used (Fig. 2). The CWG developed individual
management algorithms for the three types with abnormal monitored values: Fig. 3 presents the algorithm for
Type B (abnormal ICP and normal P
 btO2), Fig. 4 presents the algorithm for Type C (normal ICP and abnormal PbtO2), and Fig. 5 presents the algorithm for Type D
(both ICP and PbtO2 abnormal).
The CWG also provides inter-tier recommendations
(Figs. 3,4,5) and guidance on Critical Neuroworsening
(Fig. 6) to assist in evaluating and managing patients
requiring increased therapeutic intensity.

Discussion
As with the first SIBICC effort that produced a management algorithm for adult sTBI patients with ICP monitoring alone [1], this work uses Delphi process-based
mechanics to provide basic evidence guiding integration
of individual treatment modalities into management
algorithms for patients with combined ICP/PbtO2 monitoring. The process amalgamated the practice-based recommendations of 42 international, experienced, clinically
active neurotrauma practitioners from those disciplines

The combination of ICP and P
 btO2 monitoring lends
itself to several possible protocol structures. One
option is to conceptualize ICP and P
 btO2 management
separately and to present them as distinct pathways, as
has been done for the paediatric sTBI guidelines [4, 5].
The other is to maintain integration of the two monitors and create separate algorithms for the three pathologic combinations of ICP and PbtO2 status. Our panel
felt that when high ICP and low PbtO2 are present concurrently ideal management would not simply reflect
a simple combination of care provided when high ICP
and low P
 btO2 each exist in isolation. In particular, the
CWG felt that mechanical ventilation requires distinct management when both high ICP and low P
 btO2
are present concurrently. In the interest of supporting
precision medicine and to ease clinical application by
providing specific, separate protocols for individual
pathological combinations, we chose to present three
distinct algorithms (Figs. 2,3,4,5). For a given combination (type B, C, or D), the relevant protocol should
be applied. Changes in clinical status should prompt
adjustment to the newly germane algorithm as well as a
thoughtful clinical approach.
Conditions of tiered treatment

The use of tiers attempts to balance the benefits and efficacy of an agent against risks inherent to its use. General
clinical management is considered tier zero. Treatment
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Fig. 3 Consensus-based algorithm for the management of severe traumatic brain injury with intracranial hypertension and normal brain oxygenation. Lower tier treatments are viewed as having a more favorable side effect profile than higher tiers and generally should be employed first. Intertier recommendations encourage patient reassessment for remediable causes of treatment resistance. See text for details. CPP cerebral perfusion
pressure, EEG electroencephalogram, EVD external ventricular drain, ICP intracranial pressure, kPa kiloPascals, MAP mean arterial pressure, PaCO2
arterial partial pressure of carbon dioxide

of intracranial hypertension or brain hypoxia will generally begin at tier one. Movement to higher tiers reflects
increasingly aggressive interventions. Here, treatments in
any given tier are considered equivalent, with the selection of one treatment over another based on individual
patient characteristics and physician discretion. During

any given episode being addressed, multiple items from
a single tier can be trialed individually or in combination
with the goal of a rapid response. The provider should
maintain awareness of the duration of any episode and
consider moving to more aggressive interventions in
a higher tier quickly if the patient is not responding. In
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Fig. 4 Consensus-based algorithm for the management of severe traumatic brain injury with brain hypoxia and normal intracranial pressure. Lower
tier treatments are viewed as having a more favorable side effect profile than higher tiers and generally should be employed first. Inter-tier recommendations encourage patient reassessment for remediable causes of treatment resistance. See text for details. CPP cerebral perfusion pressure,
EEG electroencephalogram, EVD external ventricular drain, ICP intracranial pressure, kPa kiloPascals, MAP mean arterial pressure, PaCO2 arterial partial
pressure of carbon dioxide

some cases, it might be preferable to skip one or more
tiers (e.g. choosing to decompress a patient with midline shift due to hemispheric swelling and very high initial ICP). No individual agent or combination thereof is

critical to success in managing TBI. Clinical judgment
must always determine the final management strategy.
Tier‐zero (Fig. 1) recommendations apply to sTBI
patients who are admitted to an ICU in whom the
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Fig. 5 Consensus-based algorithm for the management of severe traumatic brain injury with intracranial hypertension and brain hypoxia. Lower
tier treatments are viewed as having a more favorable side effect profile than higher tiers and generally should be employed first. Inter-tier recommendations encourage patient reassessment for remediable causes of treatment resistance. See text for details. CPP cerebral perfusion pressure,
EEG electroencephalogram, EVD external ventricular drain, ICP intracranial pressure, kPa kiloPascals, MAP mean arterial pressure, PaCO2 arterial partial
pressure of carbon dioxide

decision to concurrently monitor ICP and PbtO2 has been
made. Management recommendations for sTBI patients
without ICP monitoring are published elsewhere [6].

The goal of tier‐zero is to establish a stable, neuroprotective physiologic baseline regardless of eventual ICP
or PbtO2 readings. Tier-zero sedatives and analgesics
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Fig. 6 Critical neuroworsening and its management. SIBICC definition (upper box), response (middle box) and a list of suggested differential diagnoses (bottom) surrounding critical neurological deterioration (critical neuroworsening). CNS central nervous system, GCS Glasgow Coma Scale, ICP
intracranial pressure

target comfort and ventilator tolerance rather than ICP
or PbtO2. Temperature management targets the avoidance of fever (defined by the CWG as core temperature > 38 °C). Consistent with the BTF Guidelines [2], the
minimal cerebral perfusion pressure (CPP) threshold is
60 mm Hg.
The algorithm for type B patients differs from that recommended for the management of intracranial hypertension in patients with ICP-monitoring alone [1] due
to available PbtO2 evidence that cerebral hypoxia is not
present. Although tiers one and two are the same as for
the ICP-only algorithm, this difference is reflected in
the recommendation that hyperventilation to a P
 aCO2
of 30–32 mmHg/4.0–4.3 kPa can be considered in tier

three. The CWG does not recommend either hypertonic
saline or mannitol as preferable and uses the same limits
for serum sodium and osmolality for both agents. They
recommend CSF drainage if an external ventricular drain
is available and consideration of placing one if other
means are used to monitor ICP. They also recommend
considering the possibility of seizures as the etiology of
intracranial hypertension in tier one.
The CWG recommends consideration of a trial of
neuromuscular blockade (with continuation if it is effective) as a tier two intervention. They also support mild
hyperventilation (PaCO2 32–35 mm Hg/4.7 kPa) at
this level. The CWG also recommends the consideration of autoregulation testing via CPP manipulation to
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determine whether CPP augmentation might be applicable. The MAP challenge is performed under stable
conditions to prevent confounding (e.g., no other active
changes in care should be made during the challenge,
including adjustments in sedation, analgesia, EVD drainage or other physiological parameters). To perform the
challenge [7]:
••  Record baseline monitor parameters at the beginning
of the challenge (e.g., ICP, MAP and CPP).
••  Initiate or titrate a vasopressor to increase the MAP
by 10 mm Hg for up to 20 min.
••  Observe the interaction between the MAP, ICP, CPP
and PbtO2 during the challenge.
••  Record monitor parameters at the end of the challenge.
••  Evaluate the observed responses and recorded values
for evidence of sPAR status. Disrupted sPAR will present as a sustained increase in ICP with MAP elevation.
••  Adjust the target MAP back to baseline (disrupted
sPAR) or to the chosen new, elevated target (intact
sPAR).
As noted above, tier three treatment in type B parallels that for ICP-monitor-only sTBI patients, with
the exception that moderate hyperventilation 
(PaCO2
30–32 mmHg/4.0–4.3 kPa) is also included.
Type C treatments include interventions known to
directly or indirectly improve PbtO2 values, largely based
upon the collective experience of the expert CWG. A
great deal of discussion surrounded augmentation of
oxygenation in terms of benefit versus toxicity and the
possibility that higher monitor readings may not parallel improved oxygen availability when F
iO2 or 
PaO2
are pushed very high. 
FiO2 can effectively increase
PbtO2 values. Although the CWG approved upward
FiO2 adjustment to 60% at tier one, further oxygenation
manipulation was left to the discretion of the physician
in terms of manipulation of ventilator dynamics, PEEP,
FiO2, etc. Therefore, at tier two, elevating the PaO2 up
to 150 mm Hg is recommended but the means is meant
to be fine-tuned to the patient. Further elevation of the
PaO2 was controversial but the final decision was to recommend normobaric hyperoxia above 150 mm Hg at tier
three.
The notion of blood transfusion to ameliorate low PbtO2
values also generated significant discussion. Harm from
the transfusion of blood products is increasingly recognized [8, 9] and many on the panel felt that transfusion
had little impact on PbtO2 values in their experience. The
CWG finally settled on limiting blood transfusion to tier
three, recommending consideration of transfusing one

unit of PRBCs in the setting of a PbtO2 < 20 mm Hg and
an Hgb < 9 g/L. It was acknowledged that blood transfusion would be a stronger consideration in patients with
active organ ischemia (eg. cardiac ischemia).
Other recommendations in type C differ from those
in type B patients. First-tier recommendations include
setting the target CPP at the upper limit of the generally accepted range of 60–70 mm Hg as blood pressure
augmentation can be an effective strategy for increasing
PbtO2. The avoidance of hypocarbia is also stressed in tier
one; hypercarbia induces vasodilation which can improve
PbtO2 though this strategy increases intracranial blood
volume and risks ICP elevation. At tier two, the CWG
supported consideration of setting an ICP threshold
below the general target of 22 mm Hg (acknowledging
that this group does not have intracranial hypertension
by definition). They also allowed compliance manipulation via CSF drainage.
Type D recommendations combine ICP and 
PbtO2
treatments, but aim to limit those treatments that
would exacerbate either pathology. At tier one, therefore, although the CWG supported elevation of the
FiO2 to 60% and setting the CPP threshold to the upper
limit of the normal range (i.e., 70 mm Hg), they recommended against hyperventilation to any degree which
could worsen PbtO2. In tier two, the CWG recommended
raising the P
 aO2 to as high as 150 mm Hg in addition to
considering neuromuscular blockade and CPP manipulation based on autoregulation testing but did not support
lowering the ICP threshold. At tier three, they combined ICP-based recommendations for pentobarbital/
thiopentone coma or decompressive craniectomy with
PbtO2-based treatments including normobaric hyperoxia
to above 150 mm Hg and limited transfusion. Notably,
decompressive craniectomy can enable more aggressive
PbtO2 augmentation strategies such as hypercarbia which
can exacerbate ICP; it can also mitigate the intracranial
hypertension associated with MAP augmentation in
patients who are not autoregulating.
The CWG carried forward those items that they did
not recommend for treating intracranial hypertension in ICP-Only patients (Table 1). They added three
PbtO2-specific items to this list. They recommended
against using high-dose barbiturates or cooling specifically for the management of PbtO2 though these therapies
can be thoughtfully administered for other indications.
They also recommended against routinely using hypercarbia (PaCO2 > 45 mm Hg/6.0 kPa in type D patients
given the risk of elevating ICP.
Inter‐tier recommendations

Stepping to a higher tier is a potential indicator of
increased disease severity. As higher tiers represent
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interventions with increased associated risks, the CWG
recommends reassessing the patient’s basic intra-and
extra-cranial physiologic status and reconsidering the
surgical status of intracranial mass lesions (e.g. contusions) not previously considered operative. If the patient
is at a non‐specialist center at the point of upward tier
advancement, the CWG recommended considering consultation with and potential transfer to a TBI center with
increased resources if possible within the regional healthcare environment. When desired, transfer is best completed before clinical decline precludes it.
Critical Neuroworsening represents a specific situation
of critical deterioration requiring emergent evaluation
and management. ‘Neuroworsening’ was first defined as
a potential intermediate-outcome variable for TBI trials
[10], it was adapted for the BEST:TRIP trial [11] and subsequent management studies for limited resource environments [6]. The CWG modified the criteria, terming
the new criteria ‘Critical Neuroworsening’ and added it
to promote its recognition as a critical event and guide
expeditious evaluation and consideration of empiric
therapy.

Summary
As with the recently published SIBICC ICP-Only algorithm [1], this effort provides a bridge between the academic value of formal evidence reports [2] and practical,
bedside management. It relies on “medicine-based-evidence” gleaned from 42 experienced, currently practicing
experts, rigorously synthesized using a Delphi-methodbased consensus process. The CWG agreed that P
 btO2
should be the second monitored variable after ICP, representing a step toward multi-modality monitoring.
These recommendations represent the lowest level of evidence—a form of multi-physician curbside consult—and
are presented as a framework for adoption or adaption
by trauma systems or medical centers toward developing
organized, protocol-based approaches to adult sTBI management. They are not binding and should not be viewed
as the only or necessarily the best method of management of sTBI. They are offered as guidance only, as a first
attempt at filling a gap in the current clinical literature.
Electronic supplementary material
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